Zhejiang Charioteer Pharmaceutical is a contract manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 8 November 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3002808516 |
| Molecule | Regulators | Docs |
|---|---|---|
| Naproxen | SFDA (Saudi Arabia), US FDA | 4 |
| Acyclovir | SFDA (Saudi Arabia), US FDA | 2 |
| Clopidogrel | SFDA (Saudi Arabia), US FDA | 2 |
| Adefovir | US FDA | 1 |
| Famciclovir | US FDA | 1 |
| Letermovir | US FDA | 1 |
| Penciclovir | US FDA | 1 |
| Valaciclovir | US FDA | 1 |
| Valganciclovir | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Charioteer Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free